CSIMarket Company Name, Ticker, Customers, else..
 
Mannkind Corporation  (NASDAQ: MNKD)
 
Price: $3.9800 $-0.03 -0.748%
Day's High: $4.005000114440918 Week Perf: -2.69 %
Day's Low: $ 3.96 30 Day Perf: 4.74 %
Volume (M): 130,060 52 Wk High: $ 6.51
Volume (M$): $ 0 52 Wk Avg: $4.44
Open: $3.96 52 Wk Low: $2.23



 Market Capitalization (Millions $) 1,227
 Shares Outstanding (Millions) 308
 Employees 592
 Revenues (TTM) (Millions $) 361
 Net Income (TTM) (Millions $) -24
 Cash Flow (TTM) (Millions $) 6
 Capital Exp. (TTM) (Millions $) 6

Business Description


Mannkind Corporation is a biopharmaceutical company that operates in the United States. The company is dedicated to the development and commercialization of therapeutic products for patients with various medical conditions. Specifically, Mannkind Corporation focuses on developing therapeutic products for the treatment of pulmonary arterial hypertension, diabetes and cancer.

One of the main products developed by Mannkind Corporation is Afrezza, a rapid-acting insulin inhalation powder that is used to treat diabetes. Afrezza is an inhalable insulin that works faster than traditional insulin injections and does not require a needle. This product is patented and provides a unique approach to the treatment of diabetes.

Apart from Afrezza, Mannkind Corporation has a number of other products in development. For pulmonary arterial hypertension, the company is developing TRE-Xi, an inhaled treatment that targets the smooth muscle cells in the pulmonary arteries. Additionally, Mannkind Corporation is also developing new technology for the delivery of inhaled drugs, which is known as the Technosphere platform technology. This proprietary platform allows for the delivery of drugs using inhalation and offers enhanced product performance and increased stability.

The company has also established various collaborations with other pharmaceutical companies to develop and commercialize its products. For instance, Mannkind Corporation has a co-promotion agreement with Sanofi-Aventis for the promotion of Afrezza globally. Similarly, the company has also entered into partnerships with United Therapeutics to develop therapies for the treatment of pulmonary arterial hypertension.

Mannkind Corporation was founded in 1991 and is headquartered in California. The company has a workforce of approximately 200 employees and has a market capitalization of approximately $255 million USD. Mannkind Corporation is listed on the NASDAQ stock exchange under the ticker symbol MNKD.


   Company Address: 1 Casper Street Danbury 6810 CT
   Company Phone Number: 661-5000   Stock Exchange / Ticker: NASDAQ MNKD


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV   -2.55%    
BMY   -0.83%    
JNJ   -1.58%    
LLY   -5.21%    
MRK   -3.75%    
PFE        1.24% 
• View Complete Report
   



Management Changes

MannKind Corporation Appoints New President, Reports Record Revenue Growth and Promising Results in Pediatric diabetes Innovations,

Published Mon, Jan 6 2025 9:30 PM UTC

MannKind Corporation Expands Leadership and Records Impressive Revenue Growth Danbury, Conn. and Westlake Village, Calif. – On January 6, 2025, MannKind Corporation (Nasdaq: MNKD), a pioneer in the development of innovative inhaled therapeutic products for patients with endocrine disorders and orphan lung diseases, announced a significant addition to its executive team. D...
Clinical Study

MannKind Advances Inhaled Therapies Promising Results in Pediatric Diabetes and Nontuberculous Mycobacterial Disease

Published Sun, Dec 29 2024 9:45 PM UTC

MannKind Corporation has recently made significant strides in the field of inhaled therapies, garnering attention with the announcement of encouraging six-month results from its Phase 3 trial investigating inhaled insulin, Afrezza, for pediatric patients with diabetes. This trial, known as INHALE-1, has shown potential in altering the management of diabetes in younger popula...
Clinical Study

MannKind Corporation Advances in Pulmonary Fibrotic Disease Treatment and Shows Stronger Financial Health

Published Mon, Nov 4 2024 11:05 AM UTC

MannKind Corporation Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases MannKind Corporation has announced a significant milestone with the successful completion of a Phase 1 clinical trial for its innovative dry powder inhaler (DPI) formulation of nintedanib, targeted at treating pulmonary fibrotic diseases. This breakthrough in the compa...
Clinical Study

Augmenting Diabetes Care Study Shows Inhaled Insulin Helps More Adults with Type 1 Diabetes Achieve A1...

Published Mon, Sep 30 2024 10:00 AM UTC

Breakthrough Study Reveals Positive Impact of Inhaled Insulin on A1C Goals for Adults with Type 1 DiabetesRecent findings from a pivotal study have unveiled encouraging results regarding the management of Type 1 diabetes. More adults with this chronic condition who transitioned from traditional insulin delivery methods specifically multiple daily injections (MDI) or automat...
Clinical Study

MannKind Corporation Secures PMDA Clearance for Phase 3 Trial of Clofazimine Inhalation Suspension in Japan

Published Wed, Sep 18 2024 10:15 AM UTC

News MannKind Corporation (NASDAQ: MNKD) has announced that it has received clearance from the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan to initiate a Phase 3 clinical trial, known as ICoN-1, evaluating clofazimine inhalation suspension for the treatment of nontuberculous mycobacterial (NTM) lung disease. This pivotal trial marks a significant milestone in ...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 3.40
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.99
Working Capital Ratio 1.87
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.07 $
Revenues (TTM) 1.17 $
Cash Flow (TTM) 0.02 $
Cash 0.43 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 609,431
Net Income per Employee (TTM) -40,395
Receivable Turnover Ratio (TTM) 13
Inventory Turnover Ratio (TTM) 1.64
Asset Turnover Ratio (TTM) 0.59

Profitability Ratios Current
Gross Margin (MRQ) 88.95 %
Operating Margin (MRQ) -1.85 %
Net Margin (MRQ) -18.43 %
Net Cash Flow Margin (MRQ) -24.45 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Mannkind's Segments
Cipla Ltd    0.11 % of total Revenue
Other Significant Segment    100 % of total Revenue
Afrezza Other Significant Segment    16.94 % of total Revenue
Furoscix Other Significant Segment    17.18 % of total Revenue
V-Go Other Significant Segment    3.48 % of total Revenue
Collaborations and services    26.08 % of total Revenue
Collaborations and services Other Significant Segment    26.08 % of total Revenue
Royalties    36.32 % of total Revenue
Royalties Other Significant Segment    36.32 % of total Revenue
Product Revenue    62.02 % of total Revenue
Services    1.66 % of total Revenue
United Therapeutics Corporation    61.84 % of total Revenue
United Therapeutics Corporation Commercial Supply    24.41 % of total Revenue
United Therapeutics Corporation License Agreement    1.11 % of total Revenue
United Therapeutics Corporation Royalties Arrangement    36.32 % of total Revenue
Collaborations and services Co-Promotion Agreement Amphastar    0.55 % of total Revenue
Collaborations and services United Therapeutics Corporation Commercial Supply Agreement    24.41 % of total Revenue
Collaborations and services United Therapeutics Corporation License Agreement    1.11 % of total Revenue
License And Service    26.08 % of total Revenue
United Therapeutics Corporation Commercial Supply Agreement License And Service    24.41 % of total Revenue
United Therapeutics Corporation License Agreement License And Service    1.11 % of total Revenue
United Therapeutics Corporation Contract Asset    32.72 % of total Revenue
Sale of product    37.6 % of total Revenue
UT CSA    24.41 % of total Revenue
UT CSA Sale of product    19.88 % of total Revenue
Other agreements UT CSA    2.63 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.